First New York Securities’s Opus Genetics IRD Stock Holding History

First New York Securities’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-31	Closed	-$13.1K	–	613
2014 Q2	$13.1K	Buy	31 +10	+48%	+$4.55K	0.01%	114
2014 Q1	$11K	Buy	+21	New	+$11.4K	0.01%	329

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First New York Securities's IRD Position: Q3 2014 in Review

First New York Securities sold out of Opus Genetics (IRD) in Q3 2014, closing a stake of 31 shares — an estimated $13.1K sold.

First New York Securities first reported a position in IRD in Q1 2014 and held it in 2 quarters. The position peaked at $13.1K in Q2 2014. 31 funds tracked by Wall St. Rank hold IRD as of Q3 2014.

First New York Securities reported no remaining Opus Genetics position as of Q3 2014 after selling out during the quarter.
First New York Securities sold 31 Opus Genetics shares in Q3 2014, an estimated $13.1K.
First New York Securities first reported a position in Opus Genetics in Q1 2014 and held it in 2 quarters.
First New York Securities's Opus Genetics position peaked at $13.1K in Q2 2014.
31 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2014.

Based on First New York Securities's 13F filing for Q3 2014, filed 16 Oct 2014.